XenTech at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
XenTech brings 2 presentations to ENA 2026 in Barcelona, and exhibits at Booth 8. Its posters cover acquired drug resistance in patient-derived models of breast cancer. The work traces olaparib resistance to restored homologous recombination and maps distinct routes of resistance to trastuzumab deruxtecan in triple-negative breast cancer.
| Organization | ENA 2026 Attendance |
|---|---|
XenTech Évry, France | |
Preclinical contract research company specialising in patient-derived xenograft models, including models of acquired resistance to targeted therapies. | Booth Exhibiting at Booth 8 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm |
Instantly find 20 buyers from XenTech
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction